Aden Tufail is one of the leading ophthalmic surgeons in the UK. He is the clinical and research lead at Moorfields Eye Hospital for age-related macular degeneration. He has worked as a consultant at Moorfields Eye Hospital since 2002 and is an Honorary Senior Lecturer at Institute of Ophthalmology, University College London. Aden’s main subspecity interest are in medical retina disorders. His current area of research includes novel therapies for dry AMD, choroidal neovascularisation and diabetic retinopathy. He has published more than 80 peer-reviewed journal articles. Most notably, he was a co-principal investigator in the seminal ABC Trial examining bevacizumab for neovascular age related macular degeneration. The ABC Trial became a cornerstone for anti-VEGF treatment protocols for wet-AMD therapy within the NHS. Current areas of interest are new treatments for choroidal neovascularisation (associated with age-related macular degeneration as well as other conditions) and novel treatments diabetic retinopathy. He is involved in laboratory as well as clinical research into treating a number of rare retinal diseases.